Dechra Pharmaceuticals Given “Hold” Rating at Nplus1 Brewin (DPH)
Dechra Pharmaceuticals (LON:DPH)‘s stock had its “hold” rating restated by Nplus1 Brewin in a research note issued on Monday, American Banking and Market News reports. They currently have a GBX 740 ($12.20) price objective on the stock. Nplus1 Brewin’s price objective would indicate a potential upside of 1.37% from the stock’s previous close.
A number of other firms have also recently commented on DPH. Analysts at N+1 Singer reiterated a “hold” rating on shares of Dechra Pharmaceuticals in a research note to investors on Monday. They now have a GBX 740 ($12.20) price target on the stock. Separately, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note to investors on Monday. They now have a GBX 800 ($13.18) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note to investors on Monday, January 6th. They now have a GBX 850 ($14.01) price target on the stock. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of GBX 774.67 ($12.77).
Dechra Pharmaceuticals (LON:DPH) opened at 725.00 on Monday. Dechra Pharmaceuticals has a 52-week low of GBX 604.00 and a 52-week high of GBX 791.50. The stock’s 50-day moving average is GBX 690.7 and its 200-day moving average is GBX 695.7. The company’s market cap is £631.9 million.
Dechra Pharmaceuticals PLC (LON:DPH) is an international veterinary pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.